Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $0.48 on Thursday, hitting $109.45. 327,049 shares of the stock traded hands, compared to its average volume of 826,821. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a 50 day simple moving average of $108.98 and a two-hundred day simple moving average of $119.28. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of 14.59, a PEG ratio of 4.72 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company's quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.68 EPS. As a group, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on JAZZ. Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $184.00.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently made changes to their positions in JAZZ. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $25,000. Quadrant Capital Group LLC raised its position in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares during the last quarter. Hurley Capital LLC purchased a new position in shares of Jazz Pharmaceuticals in the first quarter worth $25,000. Elequin Capital LP boosted its position in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. Finally, CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.